Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03423706|
Recruitment Status : Recruiting
First Posted : February 6, 2018
Last Update Posted : February 6, 2018
|Condition or disease||Intervention/treatment||Phase|
|CD19-chimeric Antigen Receptor T Cells Relapsed and/or Refractory Acute Lymphoblastic Leukemia the Haploidentical Hematopoietic Stem Cell Transplantation||Procedure: the new model of haplo-HSCT for r/r B-ALL||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation|
|Estimated Study Start Date :||March 2018|
|Estimated Primary Completion Date :||July 2018|
|Estimated Study Completion Date :||December 2020|
Experimental: new model of haplo-HSCT
use the new model of haplo-HSCT to treat the r/r B-ALL patients matching the inclusion criterion
Procedure: the new model of haplo-HSCT for r/r B-ALL
take advantage of high-dose CTX、CD19-CART、donor CD34+HSC and Tregs to create a new model of haplo-HSCT for the patients in r/r B-ALL,to improve the quality of HSCT.
- disease free survival at six months [ Time Frame: six months ]the disease free survival of the new model haplo-HSCT will be assessed at 6 months.
- acute graft-versus-host disease [ Time Frame: three months ]we will examine the treatment-related acute GVHD at 3 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03423706
|Contact: min li li, email@example.com|
|First affiliated hospital of Harbin medical university||Recruiting|
|Harbin, Heilongjiang, China, 150001|
|Contact: min li li, master 13796615495 firstname.lastname@example.org|
|Study Chair:||jin zhou, doctor||First affliliated hospital of Harbin medical university|